Background: Nowadays, emergence of Carbapenemase-Producing Enterobacterales (CPE) throughout the world has become a public health problem, especially in countries with limited resources. In recent years, CPE of type OXA-48 (Ambler class D) have been identified in Dakar. The aim of this study was to evaluate the phenotypic detection of OXA-48 CPE using a temocillin disc (30 μg). Methodology: A retrospective study was carried out at Medical Biology Laboratory of Pasteur Institute in Dakar on Ertapenem-Resistant Enterobacterales (ERE) strains isolated from 2015 to 2017. These strains were then tested with a 30 μg temocillin disc. Any strain resistant to temocillin (inhibition diameter < 12 mm) was considered to be OXA-48 CPE. Confirmation of OXA-48 CPE was performed by PCR and sequencing. Results: Forty-one ERE isolated during the study period were tested, of which 34 (82.9%) were OXA-48 based on phenotypic detection using temocillin disc and confirmed by PCR (100%). OXA-48 CPE strains detected were composed of Klebsiella pneumoniae (n = 14; 41.2%), Enterobacter cloacae (n = 8; 23.5%), Escherichia coli (n = 7, 20.5%), Citrobacter freundii (n = 3; 8.8%), Cronobacter sakazakii (n = 1; 3%) and Morganella morganii (n = 1; 3%). Conclusion: Temocillin resistance has a good positive predictive value for detecting OXA-48 CPE by phenotypic method, confirmed by PCR. Temocillin is therefore a good marker for detection of OXA-48 CPE except Hafnia alvei.
References
[1]
OMS (2017) Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. https://remed.org/wp-content/uploads/2017/03/lobal-priority-list-of-antibiotic-resistant-bacteria-2017.pdf
[2]
Nordmann, P. and Poirel, L. (2014) The Difficult-to-Control Spread of Carbapenemase Producers among Enterobacteriaceae Worldwide. Clinical Microbiology and Infection, 20, 821-830. https://doi.org/10.1111/1469-0691.12719
[3]
Patel, G., Huprikar, S., Factor, S.H., Jenkins S.G. and Calfee, D.P. (2008) Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies. Infection Control & Hospital Epidemiology, 29, 1099-1106. https://doi.org/10.1086/592412
[4]
Potron, A., Poirel, L., Rondinaud, E. and Nordmann, P. (2013) Intercontinental Spread of OXA-48 Beta-Lactamase-Producing Enterobacteriaceae over a 11-Year Period, 2001 to 2011. Eurosurveillance, 18, Article 20549. https://doi.org/10.2807/1560-7917.ES2013.18.31.20549
[5]
Nordmann, P., Cuzon, G. and Naas, T. (2009) The Real Threat of Klebsiella pneumoniae Carbapenemase-Producing Bacteria. The Lancet Infectious Diseases, 9, 228-236. https://doi.org/10.1016/S1473-3099(09)70054-4
[6]
Poirel, L., Potron, A. and Nordmann, P. (2012) OXA-48-Like Carbapenemases: The Phantom Menace. Journal of Antimicrobial Chemotherapy, 67, 1597-1606. https://doi.org/10.1093/jac/dks121
[7]
Poirel, L., Héritier, C., Tolün, V. and Nordmann, P. (2004) Emergence of Oxacillinase-Mediated Resistance to Imipenem in Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 48, 15-22. https://doi.org/10.1128/AAC.48.1.15-22.2004
[8]
Hays, C., Benouda, A., Poirel, L., Elouennass, M. and Nordmann, P. (2012) Nosocomial Occurrence of OXA-48-Producing Enterobacterial Isolates in a Moroccan Hospital. International Journal of Antimicrobial Agents, 39, 545-547. https://doi.org/10.1016/j.ijantimicag.2012.03.002
[9]
Poirel, L., Benouda, A., Hays, C. and Nordmann, P. (2011) Emergence of NDM-1-Producing Klebsiella pneumoniae in Morocco. Journal of Antimicrobial Chemotherapy, 66, 2781-2783. https://doi.org/10.1093/jac/dkr384
[10]
Moquet, O., Bouchiat, C., Kinana, A., Seck, A., Arouna, O., Bercion, R., et al. (2011) Class D OXA-48 Carbapenemase in Multidrug-Resistant Enterobacteria, Senegal. Emerging Infectious Diseases, 17, 143-144. https://doi.org/10.3201/eid1701.100244
[11]
van Duin, D. and Doi, Y. (2017) The Global Epidemiology of Carbapenemase-Producing Enterobacteriaceae. Virulence, 8, 460-469. https://doi.org/10.1080/21505594.2016.1222343
[12]
Laterre, P.F., Wittebole, X., Van de Velde, S., Muller, A.E., Mouton, J.W., Carryn, S., et al. (2015) Temocillin (6 g Daily) in Critically Ill Patients: Continuous Infusion versus Three Times Daily Administration. Journal of Antimicrobial Chemotherapy, 70, 891-898. https://doi.org/10.1093/jac/dku465
[13]
Gröbner, S., Linke, D., Schütz, W., Fladerer, C., Madlung, J., Autenrieth, I.B., et al. (2009) Emergence of Carbapenem-Non-Susceptible Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae Isolates at the University Hospital of Tübingen, Germany. Journal of Medical Microbiology, 58, 912-922. https://doi.org/10.1099/jmm.0.005850-0
[14]
Dortet, L., Poirel, L. and Nordmann, P. (2013) épidémiologie, détection et identification des entérobactéries productrices de carbapénèmases. Feuillets de Biologie, 312, 1-13.
[15]
Jousset, A.B., Emeraud, C., Bonnin, R.A., Naas, T. and Dortet, L. (2021) Caractéristiques et évolution des Souches d’Entérobactéries Productrices de Carbapénémases (EPC) Isolées en France, 2012-2020. [Characteristics and Evolution of Carbapenemase-Producing Enterobacterales in France, 2012-2020]. Bulletin Epidémiologique Hebdomadaire, 18, 351-358.
[16]
Nordmann, P., Dortet, L. and Poirel, L. (2012) Carbapenem Resistance in Enterobacteriaceae: Here Is the Storm! Trends in Molecular Medicine, 18, 263-272. https://doi.org/10.1016/j.molmed.2012.03.003
[17]
Petti, C.A., Polage, C.R., Quinn, T.C., Ronald, A.R. and Sande, M.A. (2006) Laboratory Medicine in Africa: A Barrier to Effective Health Care. Clinical Infectious Diseases, 42, 377-382. https://doi.org/10.1086/499363
[18]
Ruppé, E., Woerther, P.L., Diop, A., Sene, A.M., Da Costa, A., Arlet, G., et al. (2009) Carriage of CTX-M-15-Producing Escherichia coli Isolates among Children Living in a Remote Village in Senegal. Antimicrobial Agents and Chemotherapy, 53, 3135-3137. https://doi.org/10.1128/AAC.00139-09
